Study Confirms Regulatory-Grade Performance and AI-Driven Clinical Utility to Advance Precision Oncology and Patient Stratification for Drug Development BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced the publication of a pivotal study, “Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort,” in Communications Medicine, a high-impact journal in the Na…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.